Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Madrigal Pharmaceuticals Inc. (MDGL)

NASDAQ: MDGL · Pharmaceutical Preparations · West Conshohocken, PA

Our rating: Positive

Positive reaffirmed at $400.43, moderate conviction, November 4, 2026.

Breaks if: The Positive call weakens if Rezdiffra's year-over-year revenue growth rate — which ran at 432% through the most recent filing — falls below 60% in either of the next two quarterly reports, signaling the commercial ramp is plateauing faster than a 9.7x revenue multiple can tolerate. It also weakens if the annualized net loss run-rate widens above $350M in either of those same two prints, indicating the cost structure is not scaling with revenue. On the upside, the call would become Cautious if a competing MASH therapy gains broad formulary parity and new-to-brand prescription share for Rezdiffra stops growing for two consecutive quarters.

Key figures

Market value$8.8B
Revenue, last 12 months$1.4B
Net income, last 12 months−$155M
Free cash flow, last 12 months−$169M
Price to earningsn/a
Free cash flow yield−1.9%
Dividend yield0.0%
Operating margin−10.7%
Return on equity−24.8%
Beta to the S&P 5000.68
Volatility, annualized50.9%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$431M50.1%$1.83$117M
June 30, 2026$364M71.2%$-1.99$19M
March 31, 2026$311M126.8%$-3.25−$171M
December 31, 2025$321M210.8%$-2.03−$133M
September 30, 2025$287M362.0%$-4.01$79M
June 30, 2025$213M1353.8%$-1.50−$47M
March 31, 2025$137Mn/a$-2.61−$89M
December 31, 2024$103Mn/a$2.00−$105M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

10 ledger entries and 83 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.